Norgestimate and medroxyprogesterone acetate do not attenuate the atheroprotective effects of 17β-estradiol in ovariectomized, apolipoprotein E–deficient mice

详细信息    查看全文

• 作者：Jennifer M. Shultz ; Xiao Dong Zhu ; Robert H. Knopp ; Renee C. LeBoeuf ; Michael E. Rosenfeld
• 关键词：Estrogen ; cholesterol ; atherosclerosis ; hormone replacement therapy ; apolipoprotein E– ; deficient mice
• 刊名：Fertility and Sterility
• 出版年：2004
• 出版时间：October 2004
• 年：2004
• 卷：82
• 期：Supplement 3
• 页码：1133-1139
• 全文大小：225 K

文摘

Objective

To determine whether progestins counteract the cardioprotective effects of estrogen.

Design

Controlled animal study.

Setting

Academic laboratory environment.

Animal(s)

Female apolipoprotein E–deficient mice.

Intervention(s)

Mice were randomly assigned to groups receiving a sham operation plus placebo pellet, bilateral gonadectomy plus placebo pellet, or gonadectomy plus one of nine combinations of estrogen/progestin SC pellets.

Main outcome measure(s)

Total plasma cholesterol, body weight, fat depot weight, uterine weight and size, and the cross-sectional area of fatty streaks in the aortic sinus were measured in each animal.

Result(s)

After 8 weeks of treatment, plasma cholesterol levels were significantly higher only in the ovariectomized and sham-operated animals that received placebo pellets. No differences in plasma cholesterol were observed relative to the type or amount of progestin administered. There was a reduction in fatty streaks in all of the hormone treatment groups as compared with both the ovariectomized and sham-operated animals that received placebo pellets.

Conclusion(s)

There were no significant differences in lesion area in response to estrogen alone or to estrogen plus the different types and doses of progestins.